Acumen Pharmaceuticals, Inc. (ABOS): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Acumen Pharmaceuticals (ABOS) is developing methods to combat Alzheimer's disease in collaboration with specialized institutes. This chart reflects the current market value on GURU.Markets at 0.00. Backed by a robust scientific foundation, Acumen Pharmaceuticals (ABOS) focuses on creating specific antibodies to neutralize neurotoxins. The business currently relies on the potential of clinical trials, as it lacks stable operating income or commercially successful products in its portfolio.
Comprehensive metric breakdowns and analytics for acumenpharm.com (ABOS)
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Acumen Pharmaceuticals|ABOS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Acumen Pharmaceuticals, Inc.|ABOS - Company Aggregate Indebtedness|Debts to Book Capitalization Acumen Pharmaceuticals, Inc|ABOS - Company Long-Term Loans and Borrowings|Company Short-Term Debts Acumen Pharmaceuticals|Quick Liquidity acumenpharm.com
- financial results and valuation multiples details:
ABOS - Final Profit|Expected Profit Acumen Pharmaceuticals|ABOS - Price to Earnings Ratio|Forward P/E Multiple Acumen Pharmaceuticals|ABOS - PEG Multiple|EV/EBITDA Multiple Acumen Pharmaceuticals, Inc|ABOS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Acumen Pharmaceuticals|ABOS - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months acumenpharm.com|ABOS - Earnings growth in current year|Expected earnings per share growth for next year Acumen Pharmaceuticals
Fundamental valuation:Acumen Pharma ABOS
For Acumen Pharmaceuticals (ABOS), which invests in costly R&D to combat Alzheimer's disease, this indicator links the total enterprise value to its operating profitability before interest and taxes. Analyzing the historical EV/EBITDA values of Acumen Pharmaceuticals allows for an assessment of market perception regarding debt risks and determines whether the current capitalization is a justified reflection of neurobiological research potential or a sign of overheated capital.
Key competitors
Biogen Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Neurocrine Corp NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|axsome.com (AXSM) - Enterprise Value to EBITDA Ratio|ACAD: EV/EBITDA Multiple|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus Corp)|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN (Biohaven Ltd) - Company Value to Operating Income Before Depreciation Ratio|Amylyx - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|PRAX: EV/EBITDA Multiple|anavex.com (AVXL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|PRTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|Enterprise Value to EBITDA Ratio Annexon Biosciences Inc. ANNX|EV/EBITDA Multiple OMER (Omeros)|EV/EBITDA Multiple neurogene.com NGNE|AC Immune SA - EV/EBITDA Multiple|Voyager Therapeutics Inc (VYGR) - Enterprise Value to EBITDA Ratio|NMRA: EV/EBITDA Multiple|Company Value to EBITDA Scilex Holding Company, Inc. (SCLX)|Enterprise Value to EBITDA Ratio TVGN|EV/EBITDA Multiple Alpha Cognition Corp|Enterprise Value to EBITDA Ratio CGTX (Cognition Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio IKT|EV/EBITDA Multiple SAVA (Cassava)|Total Company Value to Operating Income Before Depreciation Ratio Assertio Holdings (ASRT)|Coya - EV/EBITDA Multiple|Vistagen Therapeutics (VTGN) - Enterprise Value to EBITDA Ratio|OVID: EV/EBITDA Multiple|CervoMed, Inc. (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc. (PEPG)|Total Company Value to Operating Income Before Depreciation Ratio jupiterneurosciences.com|EV/EBITDA Multiple RLMD (Relmada Therapeutics, Inc.)|EV/EBITDA Multiple Annovis Bio Inc ANVS|Grace Tx - EV/EBITDA Multiple|AIFF: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|MetaVia, Inc. (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|heliusmedical.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Company Value to EBITDA|NERV: Enterprise Value to EBITDA Ratio|ATHA - EV/EBITDA Multiple|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Alzamend Neuro - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Company Value to EBITDA Protagenic PTIX|EV/EBITDA Multiple KTTA|EV/EBITDA Multiple cortigent.com (CRGT)|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|BCLI - Enterprise Value to EBITDA Ratio|CARA: Enterprise Value to EBITDA Ratio|CHRO - EV/EBITDA Multiple|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Intra-Cellular Therapies, Inc.|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Marinus Pharma MRNS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|neurobopharma.com - Enterprise Value to Operating Income Before Depreciation|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VIGL|WENA: EV/EBITDA Multiple|cerevel.com - Business Value to Operating Income Before Depreciation
